Can Drugs Targeting Tumor Microenvironment Unleash Cancer Vaccine Potential?
This article was originally published in Pharmaceutical Approvals Monthly
Cancer vaccines in the past have failed clinically but may have succeeded biologically, according to Roche R&D exec Hy Levitsky. The immunosuppressive tumor microenvironment must be circumvented if the vaccine response is to be effective – and Roche thinks its immuno-oncology pipeline could do the trick.
You may also be interested in...
A trio of well-funded and star-studded new private biotechs have emerged in recent months to develop personalized cancer vaccines against tumor-specific neoantigens. After years of failure in the space, will Neon Therapeutics, Gritstone Oncology, Caperna and the rest of the field catch the wave of immuno-oncology science and sentiment?
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
Tropical diseases were not neglected by the Center for Biologics Evaluation and Research in 2019, producing three novel vaccines (which earned three priority review vouchers) and tilting the approval class toward expedited review programs.